Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 8;17:853–863. doi: 10.2147/JIR.S428305

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 Li et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

XJDHT improves sepsis-induced myocardial pathological changes. (A) Hematoxylin and eosin staining (n = 5; scale bar = 50 µm; magnification, x400). All values are presented as the mean ± SD; *P < 0.05 LPS+NS vs control group; #P < 0.05 LPS+NS + XJDHT vs LPS group. (B) ELISA demonstrated reduced serum levels of TNF-α, cTnI, and IL-1β following treatment with XJDHT. (C and D) Western blotting to determine levels of TLR4 and NF-κb after XJDHT treatment. *P < 0.05 LPS+NS vs control group; #P < 0.05 LPS+NS + XJDHT vs LPS group.